Headache Impact News Today

Fatigue was positively correlated with the frequency, duration, severity, and chronicity of migraine episodes, as well as excessive daytime sleepiness.

Fremanezumab demonstrated safety and efficacy in monthly migraine and headache reduction among patients with difficult-to-treat migraines.

Long-term benefits of Vyepti® confirmed by new data presented at the annual meeting of the American Headache SocietyAn extension phase of the DELIVER study with Vyepti® (eptinezumab) demonstrated long-lasting migraine preventive effects with treatment for up to 18 months, reducing both frequency and severity...

A brief group education and self-management program does not improve headache-related quality of life in patients with chronic migraine.

BOSTON — Headache-related quality of life lagged clinical improvement in headaches for individuals with long COVID at 12 to 19 months, according to a poster from the American Academy of Neurology annual meeting.“It helps to understand what the risks of long COVID are for patients who may previously suffer from headache in order to monitor and treat these patients in a way that is most

/PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that new data from its migraine portfolio will be presented at the Migraine Trust International Symposium...

AbbVie today announced that new data from its migraine portfolio will be presented at the Migraine Trust International Symposium (MTIS) 2022, taking place in London from September 8-11.

However, no significant benefit seen for migraine pain intensity.

Yoga therapy may reduce the frequency of headaches for people with migraine.

ROCKAWAY, N.J., Jan. 10, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced...